TORONTO, ONTARIO–(Marketwired – April 17, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) announced today the board has appointed Claude Allary as an interim director.
Allary currently is in Paris working as independent consultant and executive coach in life sciences. He was most recently a managing partner of Bionest, a pharmaceutical consulting firm with offices in Paris and New York that he co-founded in 2003. Prior to Bionest, Mr Allary accumulated over 20 years of experience within the pharmaceutical industry, successively with Rhône-Poulenc Santé (now Sanofi), Parke-Davis (now Pfizer) and Glaxo. He also spent 7 years with Arthur D. Little in London, Brussels and Paris, followed by 4 years with ISO Health Care Group. He has been an advisor to Arch since 2012.
“We are pleased to have Mr. Allary join the board of Arch. His wealth of knowledge and experience will benefit the Company as it builds out its team and pursues commercial opportunities” said Richard Muruve, CEO and director of Arch.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company’s lead technology is in the area of targeting brain tumor initiating cells for the purpose of developing new imaging, diagnostic and therapeutic treatments for malignant glioma. The Company’s website address is: www.archbiopartners.com.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.